AAV Mediated Expression of Activated Factor V (FVa) for Hemophilia

被引：0
|
作者：
Sun, Junjiang [1 ,2 ]
Chai, Zheng [1 ]
Chen, Xiaojin [1 ]
Ralph, Taylor [1 ]
Nichols, Timothy C. [3 ]
Li, Chengwen [1 ]
机构：
[1] Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA
[3] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA
来源：
MOLECULAR THERAPY | 2020年 / 28卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
943
引用
收藏
页码：410 / 411
页数：2
相关论文
共 50 条
  • [21] The use of factor IX variants improves AAV-mediated gene therapy for hemophilia B.
    Schuettrumpf, J
    Herzog, RW
    Kaufhold, A
    Stafford, DW
    High, KA
    Arruda, VR
    BLOOD, 2002, 100 (11) : 17A - 17A
  • [22] Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A
    Lee, DH
    Walker, IR
    Teitel, J
    Poon, MC
    Ritchie, B
    Akabutu, J
    Sinclair, GD
    Pai, M
    Wu, JWY
    Reddy, S
    Carter, C
    Growe, G
    Lillicrap, D
    Lam, M
    Blajchman, MA
    THROMBOSIS AND HAEMOSTASIS, 2000, 83 (03) : 387 - 391
  • [23] AAV-mediated gene therapy for hemophilia B.
    High, K
    Arruda, V
    Couto, L
    McClelland, A
    Kay, M
    Glader, B
    Herzog, R
    FASEB JOURNAL, 2000, 14 (08): : A1310 - A1310
  • [24] Immune responses to AAV and to Factor IX in a phase I study of AAV-mediated, liver-directed gene transfer for hemophilia B
    High, K
    Manno, C
    Sabatino, D
    Hutchison, S
    Dake, M
    Razavi, M
    Kaye, R
    Aruda, V
    Herzog, R
    Rustagi, P
    Rasko, J
    Hoots, K
    Blatt, P
    Sommer, J
    Ragni, M
    Ozelo, M
    Konkle, B
    Lessard, R
    Luk, A
    Glader, B
    Pierce, G
    Couto, L
    Kay, M
    MOLECULAR THERAPY, 2004, 9 : S383 - S384
  • [25] Factor VIII Immunogenicity Is a Barrier to AAV Gene Therapy for Hemophilia A
    Lytle, Allison M.
    Brown, Harrison C.
    Spencer, H. Trent
    Doering, Christopher B.
    MOLECULAR THERAPY, 2015, 23 : S95 - S96
  • [26] AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B
    Sarangi, Pratiksha
    Kumar, Narendra
    Sambasivan, Ramkumar
    Ramalingam, Sivaprakash
    Amit, Sonal
    Chandra, Dinesh
    Jayandharan, Giridhara R.
    THROMBOSIS RESEARCH, 2024, 238 : 151 - 160
  • [27] Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle
    Larson, PJ
    High, KA
    HEMOPHILIA CARE IN THE NEW MILLENNIUM, 2001, 489 : 45 - 57
  • [28] Stable Factor IX Activity Following AAV-Mediated Gene Transfer in Patients with Severe Hemophilia B
    Davidoff, Andrew
    Tuddenham, Edward G. D.
    Rangarajan, Savita
    Rosales, Cecilia
    McIntosh, Jenny
    Chowdary, Pratima
    Riddell, Anne
    Glader, Bertil
    Rustagi, Pradip
    Ng, Catherine
    Kay, Mark
    Zhou, Junfang
    Spence, Yunyu
    Morton, Christopher
    Allay, James
    Sleep, Susan
    Basner-Tschakarjan, Etiena
    Mingozzi, Federico
    High, Katherine A.
    Gray, John T.
    Reiss, Ulrike M.
    Nienhuis, Arthur W.
    Nathwani, Amit C.
    BLOOD, 2012, 120 (21)
  • [29] Towards AAV5-Mediated Gene Therapy for Hemophilia A with a Factor IX Variant that Functions Independently of FVIII
    Liu, Ying Poi
    Zancanella, Vanessa
    Au, Betty
    Montenegro-Miranda, Paula
    de Haan, Martin
    Strijbis, Viola J. F.
    Bos, Mettine H. A.
    Huber, Karin
    Schwaeble, Joachim
    Seifried, Erhard
    Konstantinova, Pavlina
    Van Deventer, Sander J.
    MOLECULAR THERAPY, 2019, 27 (04) : 442 - 442
  • [30] AAV-MEDIATED GENE THERAPY FOR HEMOPHILIA B-EXPRESSION AT THERAPEUTIC LEVELS WITH LOW VECTOR DOSES
    High, K. A.
    George, L.
    Sullivan, S.
    Luk, A.
    Urich, T.
    Teitel, J.
    Cuker, A.
    Wright, F.
    Chen, Y.
    Hui, D.
    Wachtel, K.
    Galvao, A.
    McMillan, L. E.
    Takefman, D.
    Carr, M. E.
    Couto, L.
    Anguela, X.
    HAEMATOLOGICA, 2016, 101 : 309 - 309
12345